RobertLouisGlanzmanMDFAAN(He/Him)
Neurology • Salt Lake City, UTConsultant in neuroscience drug development and medical affairs.
Dr. Glanzman is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
123 East 2nd Avenue
Salt Lake City, UT 84103Phone+1 415-535-9032- Is this information wrong?
Summary
- I am a board certified neurologist and Fellow of the American Academy of Neurology. I have extensive experience in drug development and medical affairs for neuroscience-related disorders.
Education & Training
Duke University HospitalResidency, Nuclear Medicine, 1991 - 1992
University of Michigan Health SystemResidency, Neurology, 1988 - 1991
Icahn School of Medicine at Mount Sinai (Cabrini)Internship, Internal Medicine, 1987 - 1988
Wake Forest School of Medicine of Wake Forest Baptist Medical CenterClass of 1987
Certifications & Licensure
UT State Medical License 2020 - 2026
NY State Medical License 2002 - 2021
MI State Medical License 1989 - 2002
NC State Medical License 1991 - 1998- American Board of Psychiatry and Neurology Neurology
Awards, Honors, & Recognition
- Fellow American Academy of Neurology, 2020
Clinical Trials
Publications & Presentations
PubMed
- 17 citationsGold Coast diagnostic criteria: Implications for ALS diagnosis and clinical trial enrollmentSteve Vucic, Toby A. Ferguson, Catherine Cummings, Michael T Hotchkin, Angela Genge, Robert Glanzman, Kasper C D Roet, Merit Cudkowicz, Matthew C. Kiernan> ;Muscle & Nerve. 2021 Aug 24
- 42 citationsEfficacy and safety of temelimab in multiple sclerosis: Results of a randomized phase 2b and extension study:Hans-Peter Hartung, Tobias Derfuss, Bruce A.C. Cree, Maria Pia Sormani, Krzysztof Selmaj, Jonathan Stutters, Ferran Prados, David G. MacManus, Hans Martin Schneble, Es...> ;Multiple Sclerosis. 2021 Jul 9
- Application of an evidence-based, out-patient treatment strategy for COVID-19: Multidisciplinary medical practice principles to prevent severe disease.Elliot M. Frohman, Nicole R. Villemarette-Pittman, Adriana Rodriguez, Robert L. Glanzman, Sarah Rugheimer, Oleg V. Komogortsev, Scott S. Zamvil, Roberto Alejandro Cruz...> ;Journal of the Neurological Sciences. 2021 Jul 15
- Join now to see all
Journal Articles
- Efficacy and safety of CNM-Au8 in amyotrophic lateral sclerosis (RESCUE-ALS study): a phase 2, randomised, double-blind, placebo-controlled trial and open label extensionSteve Vucic,a,∗ Parvathi Menon,a William Huynh,b Colin Mahoney,b Karen S. Ho,c Alan Hartford,c Austin Rynders,c Jacob Evan,c Jeremy Evan,c Shelia Ligozio,d Robert Glan..., eClinicalMedicine, 6/8/2023
Press Mentions
StockWatch: Despite Approval in ALS, Amylyx Sees No Price SurgeOctober 6th, 2022- Early CNM-Au8 Continues to Show Survival Benefits in ALS PatientsSeptember 27th, 2022
- Clene Nanomedicine Presents Updated Long-Term Survival Data from RESCUE-ALS Participants at 2022 AANEM Scientific ConferenceSeptember 21st, 2022
- Join now to see all
Professional Memberships
- Fellow
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
